The Physiology and Pharmacology of the CFTR Cl- Channel

Advances in Molecular and Cell Biology

Volumn 38, Issue , 2006, Pages 109-143

  Cai, Zhiwei ^a   Chen, Jeng Haur ^a   Hughes, Lauren K ^a   Li, Hongyu ^a   Sheppard, David N ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33846622413     PISSN: 15692558     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1569-2558(06)38005-8     Document Type: Chapter

References (131)

1. Ai T., Bompadre S.G., Wang X., Hu S., Li M., and Hwang T.-C. Capsaicin potentiates wild-type and mutant cystic fibrosis transmembrane conductance regulator chloride-channel currents. Mol. Pharmacol. 65 (2004) 1415-1426
2. Aleksandrov A.A., Aleksandrov L., and Riordan J.R. Nucleoside triphosphate pentose ring impact on CFTR gating and hydrolysis. FEBS Lett. 518 (2002) 183-188
3. Aleksandrov L., Aleksandrov A.A., Chang X.-B., and Riordan J.R. The first nucleotide binding domain of cystic fibrosis transmembrane conductance regulator is a site of stable nucleotide interaction, whereas the second is a site of rapid turnover. J. Biol. Chem. 277 (2002) 15419-15425
4. Amaral M.D. Processing of CFTR: Traversing the cellular maze-how much CFTR needs to go through to avoid cystic fibrosis?. Pediatr. Pulmonol. 39 (2005) 479-491
5. Anderson M.P., Berger H.A., Rich D.P., Gregory R.J., Smith A.E., and Welsh M.J. Nucleoside triphosphates are required to open the CFTR chloride channel. Cell 67 (1991) 775-784
6. Anderson M.P., Gregory R.J., Thompson S., Souza D.W., Paul S., Mulligan R.C., Smith A.E., and Welsh M.J. Demonstration that CFTR is a chloride channel by alteration of its anion selectivity. Science 253 (1991) 202-205
7. Becq F. On the discovery and development of CFTR chloride channel activators. Curr. Pharm. Des. 12 (2006) 471-484
8. Boletta A., Qian F., Onuchic L.F., Bhunia A.K., Phakdeekitcharoen B., Hanaoka K., Guggino W., Monaco L., and Germino G.G. Polycystin-1, the gene product of PKD1, induces resistance to apoptosis and spontaneous tubulogenesis in MDCK cells. Mol. Cell 6 (2000) 1267-1273
9. Brill S.R., Ross K.E., Davidow C.J., Ye M., Grantham J.J., and Caplan M.J. Immunolocalization of ion transport proteins in human autosomal dominant polycystic kidney epithelial cells. Proc. Natl. Acad. Sci. USA 93 (1996) 10206-10211
10. Cai Z., and Sheppard D.N. Phloxine B interacts with the cystic fibrosis transmembrane conductance regulator at multiple sites to modulate channel activity. J. Biol. Chem. 277 (2002) 19546-19553
11. - channel. Virtual repository of the cystic fibrosis European network (2003). http://central.igc.gulbenkian.pt/cftr/vr/physiology.html
12. - channel. J. Gen. Physiol. 122 (2003) 605-620
13. Cai Z., Scott-Ward T.S., Li H., Schmidt A., and Sheppard D.N. Strategies to investigate the mechanism of action of CFTR modulators. J. Cyst. Fibros. 3 Suppl. 2 (2004) 141-147
14. - channel. J. Biol. Chem. 281 (2006) 1970-1977
15. - channels. J. Biol. Chem. 270 (1995) 20466-20472
16. Chappe V., Mettey Y., Vierfond J.M., Hanrahan J.W., Gola M., Verrier B., and Becq F. Structural basis for specificity and potency of xanthine derivatives as activators of the CFTR chloride channel. Br. J. Pharmacol. 123 (1998) 683-693
17. Chen J.-H., Cai Z., Li H., and Sheppard D.N. Function of CFTR protein: Ion transport. In: Bush A., Alton E.W.F.W., Davies J.C., Griesenbach U., and Jaffe A. (Eds). Cystic Fibrosis in the 21st Century (2006), Karger, Basel, Switzerland 38-44
18. Cheng S.H., Gregory R.J., Marshall J., Paul S., Souza D.W., White G.A., O'Riordan C.R., and Smith A.E. Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 63 (1990) 827-834
19. Cheng S.H., Rich D.P., Marshall J., Gregory R.J., Welsh M.J., and Smith A.E. Phosphorylation of the R domain by cAMP-dependent protein kinase regulates the CFTR chloride channel. Cell 66 (1991) 1027-1036
20. Cheung M., and Akabas M.H. Identification of cystic fibrosis transmembrane conductance regulator channel-lining residues in and flanking the M6 membrane-spanning segment. Biophys. J. 70 (1996) 2688-2695
21. Csanády L., Chan K.W., Seto-Young D., Kopsco D.C., Nairn A.C., and Gadsby D.C. Severed channels probe regulation of gating of cystic fibrosis transmembrane conductance regulator by its cytoplasmic domains. J. Gen. Physiol. 116 (2000) 477-500
22. Dalemans W., Barbry P., Champigny G., Jallat S., Dott K., Dreyer D., Crystal R.G., Pavirani A., Lecocq J.-P., and Lazdunski M. Altered chloride ion channel kinetics associated with the ΔF508 cystic fibrosis mutation. Nature 354 (1991) 526-528
23. DeBin J.A., Maggio J.E., and Strichartz G.R. Purification and characterization of chlorotoxin, a chloride channel ligand from the venom of the scorpion. Am. J. Physiol. 264 (1993) C361-C369
24. Delmas P., Nomura H., Li X., Lakkis M., Luo Y., Segal Y., Fernández-Fernández J.M., Harris P., Frischauf A.-M., Brown D.A., and Zhou J. Constitutive activation of G-proteins by polycystin-1 is antagonized by polycystin-2. J. Biol. Chem. 277 (2002) 11276-11283
25. Denning G.M., Anderson M.P., Amara J.F., Marshall J., Smith A.E., and Welsh M.J. Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 358 (1992) 761-764
26. Dérand R., Bulteau-Pignoux L., and Becq F. The cystic fibrosis mutation G551D alters the non-Michaelis-Menten behaviour of the cystic fibrosis transmembrane conductance regulator (CFTR) channel and abolishes the inhibitory genistein binding site. J. Biol. Chem. 277 (2002) 35999-36004
27. Dormer R.L., Dérand R., McNeilly C.M., Mettey Y., Bulteau-Pignoux L., Métayé T., Vierfond J.-M., Gray M.A., Galietta L.J.V., Morris M.R., Pereira M.M.C., Doull I.J.M., et al. Correction of delF508-CFTR activity with benzo(c)quinolizinium compounds through facilitation of its processing in cystic fibrosis airway cells. J. Cell Sci. 114 (2001) 4073-4081
28. Dormer R.L., Harris C.M., Clark Z., Pereira M.M.C., Doull I.J.M., Norez C., Becq F., and McPherson M.A. Sildenafil (Viagra) corrects ΔF508-CFTR location in nasal epithelial cells from patients with cystic fibrosis. Thorax 60 (2005) 55-59
29. Droogmans G., Prenen J., Eggermont J., Voets T., and Nilius B. Voltage-dependent block of endothelial volume-regulated anion channels by calix[4]arenes. Am. J. Physiol. 275 (1998) C646-C652
30. Du K., Sharma M., and Lukacs G.L. The ΔF508 cystic fibrosis mutation impairs domain-domain interactions and arrests post-translational folding of CFTR. Nat. Struct. Mol. Biol. 12 (2006) 17-25
31. Engelhardt J.F., Yankaskas J.R., Ernst S.A., Yang Y., Marino C.R., Boucher R.C., Cohn J.A., and Wilson J.M. Submucosal glands are the predominant site of CFTR expression in the human bronchus. Nat. Genet. 2 (1992) 240-248
32. Forstner G., Kopelman H., Durie P., and Corey M. Pancreatic and intestinal dysfunction in cystic fibrosis. In: Riordan J.R., and Buchwald M. (Eds). Genetics and Epithelial Cell Dysfunction in Cystic Fibrosis (1987), Alan R. Liss, New York 7-17
33. Fuller M.D., Zhang Z.-R., Cui G., Kubanek J., and McCarty N.A. Inhibition of CFTR channels by a peptide toxin of scorpion venom. Am. J. Physiol. 287 (2004) C1328-C1341
34. Fuller M.D., Zhang Z.-R., Cui G., and McCarty N.A. The block of CFTR by scorpion venom is state-dependent. Biophys. J. 89 (2005) 3960-3975
35. Gabriel S.E., Brigman K.N., Koller B.H., Boucher R.C., and Stutts M.J. Cystic fibrosis heterozygote resistance to cholera toxin in the cystic fibrosis mouse model. Science 266 (1994) 107-109
36. Gadsby D.C., and Nairn A.C. Control of cystic fibrosis transmembrane conductance regulator channel gating by phosphorylation and nucleotide hydrolysis. Physiol. Rev. 79 (1999) S77-S107
37. Gadsby D.C., Vergani P., and Csanády L. The ABC protein turned chloride channel whose failure causes cystic fibrosis. Nature 440 (2006) 477-483
38. Galietta L.J.V., Springsteel M.F., Eda M., Niedzinski E.J., By K., Haddadin M.J., Kurth M.J., Nantz M.H., and Verkman A.S. Novel CFTR chloride channel activators identified by screening of combinatorial libraries based on flavone and benzoquinolizinium lead compounds. J. Biol. Chem. 276 (2001) 19723-19728
39. Gong X., and Linsdell P. Maximization of the rate of chloride conduction in the CFTR channel pore by ion-ion interactions. Arch. Biochem. Biophys. 426 (2004) 78-82
40. - channel pore. J. Physiol. 540 (2002) 39-47
41. 2+-permeable nonselective cation channel. Proc. Natl. Acad. Sci. USA 98 (2001) 1182-1187
42. Gribkoff V.K., Champigny G., Barbry P., Dworetzky S.I., Meanwell N.A., and Lazdunski M. The substituted benzimidazolone NS004 is an opener of the cystic fibrosis chloride channel. J. Biol. Chem. 269 (1994) 10983-10986
43. Grimard V., Li C., Ramjeesingh M., Bear C.E., Goormaghtigh E., and Ruysschaert J.-M. Phosphorylation-induced conformational changes of cystic fibrosis transmembrane conductance regulator monitored by attenuated total reflection-fourier transform IR spectroscopy and fluorescence spectroscopy. J. Biol. Chem. 279 (2004) 5528-5536
44. Guerrant R.L., Hughes J.M., Lima N.L., and Crane J. Diarrhea in developed and developing countries: Magnitude, special settings, and etiologies. Rev. Infect. Dis. 12 (1990) S41-S50
45. Guggino W.B., and Stanton B.A. New insights into cystic fibrosis: Molecular switches that regulate CFTR. Nat. Rev. Mol. Cell Biol. 7 (2006) 426-436
46. Gunderson K.L., and Kopito R.R. Effects of pyrophosphate and nucleotide analogs suggest a role for ATP hydrolysis in cystic fibrosis transmembrane regulator channel gating. J. Biol. Chem. 269 (1994) 19349-19353
47. Gupta J., and Linsdell P. Point mutations in the pore region directly or indirectly affect glibenclamide block of the CFTR chloride channel. Pflügers Arch. 443 (2002) 739-747
48. Hallows K.R., Raghuram V., Kemp B.E., Witters L.A., and Foskett J.K. Inhibition of cystic fibrosis transmembrane conductance regulator by novel interaction with the metabolic sensor AMP-activated protein kinase. J. Clin. Invest. 105 (2000) 1711-1721
49. Hallows K.R., McCane J.E., Kemp B.E., Witters L.A., and Foskett J.K. Regulation of channel gating by AMP-activated protein kinase modulates cystic fibrosis transmembrane conductance regulator activity in lung submucosal cells. J. Biol. Chem. 278 (2003) 998-1004
50. Hanaoka K., and Guggino W.B. cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells. J. Am. Soc. Nephrol. 11 (2000) 1179-1187
51. Hanaoka K., Devuyst O., Schwiebert E.M., Wilson P.D., and Guggino W.B. A role for CFTR in human autosomal dominant polycystic kidney disease. Am. J. Physiol. 270 (1996) C389-C399
52. Hanrahan J.W., Gentzsch M., and Riordan J.R. The cystic fibrosis transmembrane conductance regulator (ABCC7). In: Holland I.B., Cole S.P.C., Higgins C.F., and Kuchler K. (Eds). ABC Proteins: From Bacteria to Man (2003), Academic Press, London 589-618
53. Holland I.B., Cole S.P.C., Kuchler K., and Higgins C.F. ABC Proteins: From Bacteria to Man (2003), Academic Press, London
54. Huang P., Lazarowski E., Tarran R., Milgram S.L., Boucher R.C., and Stutts M.J. Compartmentalized autocrine signaling to cystic fibrosis transmembrane conductance regulator at the apical membrane of airway epithelial cells. Proc. Natl. Acad. Sci. USA 98 (2001) 14120-14125
55. Hume J.R., Duan D., Collier M.L., Yamazaki J., and Horowitz B. Anion transport in heart. Physiol. Rev. 80 (2000) 31-81
56. - channel. Trends Pharmacol. Sci. 20 (1999) 448-453
57. - conductance in mammalian heart. J. Gen. Physiol. 101 (1993) 629-650
58. Kidd J.F., Ramjeesingh M., Stratford F., Huan L.-J., and Bear C.E. A heteromeric complex of the two nucleotide binding domains of cystic fibrosis transmembrane conductance regulator (CFTR) mediates ATPase activity. J. Biol. Chem. 279 (2004) 41664-41669
59. Ko S.B.H., Zeng W., Dorwart M.R., Luo X., Kim K.H., Millen L., Goto H., Naruse S., Soyombo A., Thomas P.J., and Muallem S. Gating of CFTR by the STAS domain of SLC26 transporters. Nat. Cell Biol. 6 (2004) 343-350
60. Koulen P., Cai Y., Geng L., Maeda Y., Nishimura S., Witzgall R., Ehrlich B.E., and Somlo S. Polycystin-2 is an intracellular calcium channel. Nat. Cell Biol. 4 (2002) 191-197
61. Lakkis M., and Zhou J. Molecular complexes formed with polycystins. Nephron Exp. Nephrol. 93 (2003) e3-e8
62. Lewis H.A., Buchanan S.G., Burley S.K., Conners K., Dickey M., Dorwart M., Fowler R., Gao X., Guggino W.B., Hendrickson W.A., Hunt J.F., Kearins M.C., et al. Structure of nucleotide-binding domain 1 of the cystic fibrosis transmembrane conductance regulator. EMBO J. 23 (2004) 282-293
63. Lewis H.A., Zhao X., Wang C., Sauder J.M., Rooney I., Noland B.W., Lorimer D., Kearins M.C., Conners K., Condon B., Maloney P.C., Guggino W.B., et al. Impact of the ΔF508 mutation in first nucleotide-binding domain of human cystic fibrosis transmembrane conductance regulator on domain folding and structure. J. Biol. Chem. 280 (2005) 1346-1353
64. Li C., Ramjeesingh M., Wang W., Garami E., Hewryk M., Lee D., Rommens J.M., Galley K., and Bear C.E. ATPase activity of the cystic fibrosis transmembrane conductance regulator. J. Biol. Chem. 271 (1996) 28463-28468
65. - secretion, and renal cyst growth: A study using CFTR inhibitors. Kidney Int. 66 (2004) 1926-1938
66. Linsdell P. Location of a common inhibitor binding site in the cytoplasmic vestibule of the cystic fibrosis transmembrane conductance regulator chloride channel pore. J. Biol. Chem. 280 (2005) 8945-8950
67. Linsdell P. Mechanism of chloride permeation in the cystic fibrosis transmembrane conductance regulator chloride channel. Exp. Physiol. 91 (2006) 123-129
68. Linsdell P., and Hanrahan J.W. Adenosine triphosphate-dependent asymmetry of anion permeation in the cystic fibrosis transmembrane conductance regulator chloride channel. J. Gen. Physiol. 111 (1998) 601-614
69. Linsdell P., Tabcharani J.A., and Hanrahan J.W. Multi-ion mechanism for ion permeation and block in the cystic fibrosis transmembrane conductance regulator chloride channel. J. Gen. Physiol. 110 (1997) 365-377
70. Linsdell P., Tabcharani J.A., Rommens J.M., Hou Y.-X., Chang X.-B., Tsui L.-C., Riordan J.R., and Hanrahan J.W. Permeability of wild-type and mutant cystic fibrosis transmembrane conductance regulator chloride channels to polyatomic anions. J. Gen. Physiol. 110 (1997) 355-364
71. Liu X., Smith S.S., and Dawson D.C. CFTR: What's it like inside the pore?. J. Exp. Zool. 300A (2003) 69-75
72. Locher K.P., Lee A.T., and Rees D.C. The E. coli BtuCD structure: A framework for ABC transporter architecture and mechanism. Science 296 (2002) 1091-1098
73. Loo T.W., Bartlett M.C., and Clarke D.M. Simultaneous binding of two different drugs in the binding pocket of the human multidrug resistance P-glycoprotein. J. Biol. Chem. 278 (2003) 39706-39710
74. Ma T., Thiagarajah J.R., Yang H., Sonawane N.D., Folli C., Galietta L.J.V., and Verkman A.S. Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion. J. Clin. Invest. 110 (2002) 1651-1658
75. Ma T., Vetrivel L., Yang H., Pedemonte N., Zegarra-Moran O., Galietta L.J.V., and Verkman A.S. High-affinity activators of cystic fibrosis transmembrane conductance regulator (CFTR) chloride conductance identified by high-throughput screening. J. Biol. Chem. 277 (2002) 37235-37241
76. Maertens C., Wei L., Tytgat J., Droogmans G., and Nilius B. Chlorotoxin does not inhibit volume-regulated, calcium-activated and cyclic AMP-activated chloride channels. Br. J. Pharmacol. 129 (2000) 791-801
77. Matsui H., Grubb B.R., Tarran R., Randell S.H., Gatzy J.T., Davis C.W., and Boucher R.C. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 95 (1998) 1005-1015
78. McCarty N.A. Permeation through the CFTR chloride channel. J. Exp. Biol. 203 (2000) 1947-1962
79. McDonough S., Davidson N., Lester H.A., and McCarty N.A. Novel pore-lining residues in CFTR that govern permeation and open-channel block. Neuron 13 (1994) 623-634
80. Melin P., Thoreau V., Norez C., Bilan F., Kitzis A., and Becq F. The cystic fibrosis mutation G1349D within the signature motif LSHGH of NBD2 abolishes the activation of CFTR chloride channels by genistein. Biochem. Pharmacol. 67 (2004) 2187-2196
81. Moran O., Galietta L.J.V., and Zegarra-Moran O. Binding site of activators of the cystic fibrosis transmembrane conductance regulator in the nucleotide binding domains. Cell. Mol. Life Sci. 62 (2005) 446-460
82. Muanprasat C., Sonawane N.D., Salinas D., Taddei A., Galietta L.J.V., and Verkman A.S. Discovery of glycine hydrazide pore-occluding CFTR inhibitors: Mechanism, structure-activity analysis and in vivo efficacy. J. Gen. Physiol. 124 (2004) 125-137
83. Naren A.P., Cobb B., Li C., Roy K., Nelson D., Heda G.D., Liao J., Kirk K.L., Sorscher E.J., Hanrahan J., and Clancy J.P. A macromolecular complex of β2 adrenergic receptor, CFTR, and ezrin/radixin/moesin-binding phosphoprotein 50 is regulated by PKA. Proc. Natl. Acad. Sci. USA 100 (2003) 342-346
84. Nauli S.M., Alenghat F.J., Luo Y., Williams E., Vassilev P., Li X., Elia A.E.H., Lu W., Brown E.M., Quinn S.J., Ingber D.E., and Zhou J. Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. Nat. Genet. 33 (2003) 129-137
85. Novak I., and Greger R. Properties of the luminal membrane of isolated perfused rat pancreatic ducts: Effect of cyclic AMP and blockers of chloride transport. Pflügers Arch. 411 (1988) 546-553
86. Ostedgaard L.S., Baldursson O., Vermeer D.W., Welsh M.J., and Robertson A.D. A functional R domain from cystic fibrosis transmembrane conductance regulator is predominantly unstructured in solution. Proc. Natl. Acad. Sci. USA 97 (2000) 5657-5662
87. - channel by its R domain. J. Biol. Chem. 276 (2001) 7689-7692
88. Pedemonte N., Sonawane N.D., Taddei A., Hu J., Zegarra-Moran O., Suen Y.F., Robins L.I., Dicus C.W., Willenbring D., Nantz M.H., Kurth M.J., Galietta L.J.V., et al. Phenylglycine and sulfonamide correctors of defective ΔF508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating. Mol. Pharmacol. 67 (2005) 1797-1807
89. - channels inferred from analysis of voltage-dependent block. J. Biol. Chem. 276 (2001) 18423-18429
90. Quinton P.M. Chloride impermeability in cystic fibrosis. Nature 301 (1983) 421-422
91. - conductance in both cell membranes of an absorptive epithelium. J. Membr. Biol. 130 (1992) 49-62
92. Reddy M.M., and Quinton P.M. Deactivation of CFTR-Cl conductance by endogenous phosphatases in the native sweat duct. Am. J. Physiol. 270 (1996) C474-C480
93. - channel by negative charge in the R domain. J. Biol. Chem. 268 (1993) 20259-20267
94. Riordan J.R. Assembly of functional CFTR chloride channels. Annu. Rev. Physiol. 67 (2005) 701-718
95. Riordan J.R., Rommens J.M., Kerem B.-S., Alon N., Rozmahel R., Grzelczak Z., Zielenski J., Lok S., Plavsic N., Chou J.-L., Drumm M.L., Iannuzzi M.C., et al. Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA. Science 245 (1989) 1066-1073
96. Rosenberg M.F., Kamis A.B., Aleksandrov L.A., Ford R.C., and Riordan J.R. Purification and crystallization of the cystic fibrosis transmembrane conductance regulator (CFTR). J. Biol. Chem. 279 (2004) 39051-39057
97. Rosenberg M.F., Callaghan R., Modok S., Higgins C.F., and Ford R.C. Three-dimensional structure of P-glycoprotein: The transmembrane regions adopt an asymmetric configuration in the nucleotide-bound state. J. Biol. Chem. 280 (2005) 2857-2862
98. Rubenstein R.C. New pharmacological approaches for treatment of cystic fibrosis. In: Bush A., Alton E.W.F.W., Davies J.C., Griesenbach U., and Jaffe A. (Eds). Cystic Fibrosis in the 21st Century (2006), Karger, Basel, Switzerland 212-220
99. Schultz B.D., Singh A.K., Devor D.C., and Bridges R.J. Pharmacology of CFTR chloride channel activity. Physiol. Rev. 79 (1999) S109-S144
100. - channel by niflumic acid. Mol. Membr. Biol. 21 (2004) 27-38
101. + channel regulators on cystic fibrosis transmembrane conductance regulator chloride currents. J. Gen. Physiol. 100 (1992) 573-591
102. Sheppard D.N., and Welsh M.J. Structure and function of the cystic fibrosis transmembrane conductance regulator chloride channel. Physiol. Rev. 79 (1999) S23-S45
103. Sheppard D.N., Ostedgaard L.S., Winter M.C., and Welsh M.J. Mechanism of dysfunction of two nucleotide binding domain mutations in cystic fibrosis transmembrane conductance regulator that are associated with pancreatic sufficiency. EMBO J. 14 (1995) 876-883
104. Short D.B., Trotter K.W., Reczek D., Kreda S.M., Bretscher A., Boucher R.C., Stutts M.J., and Milgram S.L. An apical PDZ protein anchors the cystic fibrosis transmembrane conductance regulator to the cytoskeleton. J. Biol. Chem. 273 (1998) 19797-19801
105. Singh A.K., Venglarik C.J., and Bridges R.J. Development of chloride channel modulators. Kidney Int. 48 (1995) 985-993
106. - secretion?. Pediatr. Pulmonol. (1996) 237 Suppl. 13
107. Smith J.J., Travis S.M., Greenberg E.P., and Welsh M.J. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 85 (1996) 229-236
108. Sonawane N.D., Hu J., Muanprasat C., and Verkman A.S. Luminally active, nonabsorbable CFTR inhibitors as potential therapy to reduce intestinal fluid loss in cholera. FASEB J. 20 (2006) 130-132
109. Springsteel M.F., Galietta L.J.V., Ma T., By K., Berger G.O., Yang H., Dicus C.W., Choung W., Quan C., Shelat A.A., Guy R.K., Verkman A.S., et al. Benzoflavone activators of the cystic fibrosis transmembrane conductance regulator: Towards a pharmacophore model for the nucleotide-binding domain. Bioorg. Med. Chem. 11 (2003) 4113-4120
110. Sullivan L.P., Wallace D.P., and Grantham J.J. Chloride and fluid secretion in polycystic kidney disease. J. Am. Soc. Nephrol. 9 (1998) 903-916
111. 84. FEBS Lett. 270 (1990) 157-164
112. Tabcharani J.A., Rommens J.M., Hou Y.-X., Chang X.-B., Tsui L.-C., Riordan J.R., and Hanrahan J.W. Multi-ion pore behaviour in the CFTR chloride channel. Nature 366 (1993) 79-82
113. Thiagarajah J.R., and Verkman A.S. CFTR pharmacology and its role in intestinal fluid secretion. Curr. Opin. Pharmacol. 3 (2003) 594-599
114. Torres V.E., Wang X., Qian Q., Somlo S., Harris P.C., and Gattone II V.H. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat. Med. 10 (2004) 363-364
115. Travis S.M., Berger H.A., and Welsh M.J. Protein phosphatase 2C dephosphorylates and inactivates cystic fibrosis transmembrane conductance regulator. Proc. Natl. Acad. Sci. USA 94 (1997) 11055-11060
116. Van Goor F., Straley K.S., Cao D., González J., Hadida S., Hazlewood A., Joubran J., Knapp T., Makings L.R., Miller M., Neuberger T., Olson E., et al. Rescue of ΔF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am. J. Physiol. 290 (2006) L1117-L1130
117. Vastiau A., Cao L., Jaspers M., Owsianik G., Janssens V., Cuppens H., Goris J., Nilius B., and Cassiman J.-J. Interaction of the protein phosphatase 2A with the regulatory domain of the cystic fibrosis transmembrane conductance regulator channel. FEBS Lett. 579 (2005) 3392-3396
118. - channels. J. Gen. Physiol. 120 (2003) 17-36
119. Vergani P., Lockless S.W., Nairn A.C., and Gadsby D.C. CFTR channel opening by ATP-driven tight dimerization of its nucleotide-binding domains. Nature 433 (2005) 876-880
120. Wang F., Zeltwanger S., Yang I.C.H., Nairn A.C., and Hwang T.-C. Actions of genistein on cystic fibrosis transmembrane conductance regulator channel gating: Evidence for two binding sites with opposite effects. J. Gen. Physiol. 111 (1998) 477-490
121. Wang F., Zeltwanger S., Hu S., and Hwang T.-C. Deletion of phenylalanine 508 causes attenuated phosphorylation-dependent activation of CFTR chloride channels. J. Physiol. 524 (2000) 637-648
122. Welsh M.J., and Smith A.E. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 73 (1993) 1251-1254
123. Welsh M.J., Ramsey B.W., Accurso F., and Cutting G.R. Cystic fibrosis. In: Scriver C.R., Beaudet A.L., Sly W.S., and Valle D. (Eds). The Metabolic and Molecular Basis of Inherited Disease (2001), McGraw-Hill Inc., New York 5121-5188
124. Wilkinson D.J., Strong T.V., Mansoura M.K., Wood D.L., Smith S.S., Collins F.S., and Dawson D.C. CFTR activation: Additive effects of stimulatory and inhibitory phosphorylation sites in the R domain. Am. J. Physiol. 273 (1997) L127-L133
125. Wilson P.D. Polycystic kidney disease. N. Engl. J. Med. 350 (2004) 151-164
126. Wine J.J. The genesis of cystic fibrosis lung disease. J. Clin. Invest. 103 (1999) 309-312
127. Winter M.C., and Welsh M.J. Stimulation of CFTR activity by its phosphorylated R domain. Nature 389 (1997) 294-296
128. Woodhull A.M. Ionic blockage of sodium channels in nerve. J. Gen. Physiol. 61 (1973) 687-708
129. Yang H., Shelat A.A., Guy R.K., Gopinath V.S., Ma T., Du K., Lukacs G.L., Taddei A., Folli C., Pedemonte N., Galietta L.J.V., and Verkman A.S. Nanomolar affinity small molecule correctors of defective ΔF508-CFTR chloride channel gating. J. Biol. Chem. 278 (2003) 35079-35085
130. Zhang Z.-R., Zeltwanger S., and McCarty N.A. Direct comparison of NPPB and DPC as probes of CFTR expressed in Xenopus oocytes. J. Membr. Biol. 175 (2000) 35-52
131. Zhu T., Dahan D., Evagelidis A., Zheng S.-X., Luo J., and Hanrahan J.W. Association of cystic fibrosis transmembrane conductance regulator and protein phosphatase 2C. J. Biol. Chem. 274 (1999) 29102-29107